Silo Pharma Inc

Silo Pharma has been granted a European patent covering the preventative approach of its lead candidate SPC-15, a novel intranasal treatment for post-traumatic stress disorder and stress-induced affective disorders. The European Patent Office issued European Patent No. EP3952852, titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” which covers methods of preventing stress-induced fear and depressive-like behavior by administering selected serotonin 4 receptor agonists before stress exposure. Silo holds an exclusive license for the patent from Columbia University. The new patent expands the intellectual property portfolio for SPC-15 and complements protection granted and pending in five other major global markets. CEO Eric Weisblum stated that the patent strengthens the company’s IP moat around a differentiated approach targeting stress resilience rather than symptom management.

Silo Pharma's wholly owned subsidiary QwikAgents has joined the NVIDIA Developer Program to support the advancement of its artificial intelligence agent integration platform. The program provides QwikAgents with access to NVIDIA's AI software ecosystem, development tools, technical resources, and optimization support aimed at improving next-generation AI applications. QwikAgents' platform is designed to automate complex business processes through autonomous AI agents capable of reasoning, executing tasks, and connecting with enterprise systems. The company expects these resources to help accelerate platform development as it expands solutions for organizations seeking scalable AI-driven operations.